Accessibility Menu
Estrella Immunopharma logo

Estrella Immunopharma(NASDAQ) ESLA

Current Price$0.76
Market Cap$33.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-92%
5 YearN/A
1 Year-18%
1 Month-20%
Estrella Immunopharma last closing stock price
MetricPriceDate
Last closeUSD 0.782026-07-24
Estrella Immunopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.14%USD 0.842026-07-17
1 month-20.41%USD 0.982026-06-24
3 month-50.63%USD 1.582026-04-24
Year to date-50%USD 1.562025-12-31
1 year-17.85%USD 0.952025-07-24
3 year-92.72%USD 10.712023-07-25
Since inception-92%USD 9.752021-09-14

Estrella Immunopharma Financials at a Glance

Market Cap

$33.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$13.25M

EPS (TTM)

-$0.35

P/E Ratio

-2.21

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.76

Volume

78,744

Open

$0.77

Previous Close

$0.78

Daily Range

$0.73 - $0.81

52-Week Range

$0.73 - $3.15

Estimated Earnings Date

Sep 2, 2026

ESLA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Estrella Immunopharma

Estrella Immunopharma develops cell therapies for people with blood cancers. Its treatments aim to help patients who do not respond to standard care. The company’s work focuses on making advanced therapies more accessible and manageable for hospitals and clinics.

Lab Bench to Bedside: Products and Services

  • EB103 (CD19 T-cell therapy): Targets relapsed B-cell lymphomas; for patients not helped by other treatments. (0% of revenue; pre-commercial)
  • EB104 (Dual-target T-cell therapy): Aims at both CD19 and CD22 proteins; designed for certain lymphomas and leukemia. (0% of revenue; pre-commercial)
  • EB201 (Autoimmune therapy): Early-stage program for systemic lupus, a chronic immune disease. (0% of revenue; pre-commercial)
  • Imugene Collaboration: Combines Estrella’s cell therapy with a virus-based approach for solid tumors. (0% of revenue; pre-commercial)

Growth Spurts and Strategic Moves

  • Partnered with Eureka Therapeutics for research, manufacturing, and technology since inception.
  • Formed a collaboration with Imugene prior to 2024 to target solid tumors, with the research plan completed by August 30, 2023.
  • Started Phase I/II clinical trial for EB103 in 2024; nine patients dosed by end of 2025.
  • Formed a Hong Kong subsidiary in November 2024 for potential future expansion.
  • Raised $2.4 million in private placement (2025) and $8 million in direct offering (January 2026).

What Makes Estrella Stand Out

Estrella’s therapies use a unique T-cell platform designed to reduce side effects and improve safety. The company relies on partnerships for all research, manufacturing, and IT, keeping operations lean. Its approach aims to make advanced cancer treatments more widely available and less costly for healthcare providers.

Five Things You Need to Know

  • No revenue reported for QQ3 2023, QQ3 2024, or QQ3 2025.
  • Net loss was $13.1 million in 2025, up 48.9% from 2024.
  • Cash used in operations was $1.8 million in 2025.
  • Cash and equivalents stood at $1.4 million as of December 31, 2025.
  • Working capital deficit reached $11.9 million at year-end 2025.

Bottom Line

Estrella remains a pre-commercial biotech focused on cell therapies for cancer. Its future depends on clinical progress, funding, and continued partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Cheng Liu, PhD

Website

www.estrellabio.com

Headquarters

EmeryVille, CA 94608, US

ESLA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

167.91%

Return on Capital

N/A

Return on Assets

-362.33%

Earnings Yield

-45.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$33.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

43.03M

Volume

78.74K

Avg. Volume

41.73K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$13.25M

EBITDA

-$13.25M

Operating Cash Flow

-$8.02M

Capital Expenditure

$0.00

Free Cash Flow

-$8.02M

Cash & ST Invst.

$1.93M

Total Debt

$0.00

Estrella Immunopharma Performance Analysis

Estrella Immunopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20242024-06-30USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Estrella Immunopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Estrella Immunopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.17307.5%
20242024-06-30USD -0.2756.1%
20242024-12-31USD -0.2456.1%
20252025-12-31USD -0.3546.3%
Estrella Immunopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-157.7%
Q32025-09-3013.3%
Q42025-12-3187.5%
Q12026-03-31-208.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$33.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.19M

N/A

Employees

3

N/A

Net Income

-$2.29M

-8.9%

EBITDA

-$2.29M

-8.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.93M

+357.3%

Total Debt

$0.00

-100.0%

Accounts Receivable

$229.79K

-56.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-3.62%

N/A

Return on Invested Capital

2.51%

N/A

Free Cash Flow

-$6.70M

-1337.4%

Operating Cash Flow

-$6.70M

-1337.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EXOZeXoZymes, Inc.
$4.71+0.21%
ATOSAtossa Therapeutics, Inc.
$2.30-4.77%
TVGNTevogen Bio Holdings Inc.
$4.49+1.81%
TILInstil Bio, Inc.
$7.13-0.97%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About ESLA

What is the current price of Estrella Immunopharma?

Estrella Immunopharma is trading at $0.78 per share.

What is the 52-week range for Estrella Immunopharma?

Over the past 52 weeks, Estrella Immunopharma has traded between $0.73 and $3.15.

How much debt does Estrella Immunopharma have?

As of the most recent reporting period, Estrella Immunopharma reported total debt of $0.00.

How much cash does Estrella Immunopharma have on hand?

Estrella Immunopharma reported $1.93M in cash and cash equivalents in its most recent financial results.

What is Estrella Immunopharma’s dividend yield?

Estrella Immunopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services